# US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

> **Open Intelligence Dossier** · First detected: 2026-11-15 23:40 UTC · Category: Business

## Executive Summary
The US FDA declines to approve Summit's China-developed lung cancer drug after its trial misses a key survival goal, sending SMMT shares plunging overnight.

## Intelligence Brief
The US Food and Drug Administration has declined to approve Summit&#039;s China-developed lung cancer drug after the drug&#039;s trial missed a key survival goal, according to coverage from Investor&#039;s Business Daily. The regulatory decision marks a setback for Summit&#039;s oncology program and leaves the drug without US market authorization. Coverage from Yahoo Finance reports that SMMT stock plunged overnight following the FDA rejection, reflecting investor reaction to the regulatory outcome. The two reports together frame the event as both a clinical and financial development for the company.


Neither outlet provides the specific survival statistics, the trial&#039;s phase, the drug&#039;s name, or the company&#039;s headquarters location in the available coverage.


The sequence suggests the rejection became public after market hours, driving the overnight decline before the regulatory story received wider coverage. The stakes involve Summit&#039;s ability to bring a lung cancer therapy to US patients and the company&#039;s valuation as reflected in its share price.


What to watch next depends on disclosures Summit or the FDA may issue regarding the trial data, any potential resubmission or appeal pathway, and whether the company provides further detail on the missed survival goal. Coverage does not yet specify the drug&#039;s name, the trial phase, the magnitude of the stock decline, or Summit&#039;s next regulatory steps.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Investor's Business Daily | FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug | [Source Link](https://news.google.com/rss/articles/CBMixAFBVV95cUxNZEpfN2h6QkhfeGdPQTFpbGc4YzJ2ZDlXd0xDR0F6ZXZOOEJBY0lNQWJDenY5WEl1NnA1dFhHMG9WYlRfOC15anNTMUZNZUlrR0dzZzZsb0ZValBFY1VXMjFJTjFMTTlxY2F6OC10aW16TUp2bmkxeDY3LVp5TXV3UUJmbnoxbE42TnZIWVZpbE9hcVV6cWliYllhVkxzSF95MzZvR3pseEgtMlVKWnkxZndjWWtxSENibWU0ZGNrdnQ2TzZR?oc=5) |
| Yahoo Finance | SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxPTFN1MGFSSVg0TDROWjNxSXpVbmVUTENkWVRXWm8wbkQ1dVd5bGhjLXFjei02ZUgycVk4RGFSZVNiSEdiQmttTGc3M2xydlJwX2o2NE0tekdsWlBlMnluNWVmRS0tM0pVTnBOTUNaQ2owYnlMZEFsV1VTbHhUaFJ6dFlfQ0o?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-15/us-fda-declines-to-approve-summit-lung-cancer-drug-after-trial-misses-key*
